FULCRUM THERAPEUTICS

3.8500

29-November-24 12:45:00

15 minutes delayed

Stocks

-0.1000

-2.53%

Today's range

3.8100 - 3.9900

ISIN

N/A

Source

NASDAQ

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 Mar 2024 15:05:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 15:30:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 Mar 2024 06:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 15:30:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

27 Feb 2024 06:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20 Feb 2024 15:01:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 07:00:01 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2023 15:30:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Nov 2023 15:30:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023

07 Nov 2023 06:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

31 Oct 2023 07:50:33 By Nasdaq GlobeNewswire
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

22 Sep 2023 07:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Sep 2023 15:30:00 By Nasdaq GlobeNewswire
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

22 Aug 2023 06:00:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Aug 2023 15:53:28 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

03 Aug 2023 06:01:00 By Nasdaq GlobeNewswire
Fulcrum Therapeutics Appoints Chief Financial Officer

03 Aug 2023 05:55:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.